{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:21:13Z","timestamp":1790835673891,"version":"4.1.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.cyto.2019.154799","type":"journal-article","created":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T06:11:51Z","timestamp":1565158311000},"page":"154799","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"special_numbering":"C","title":["Interleukin-4 and interleukin-13 as possible therapeutic targets in systemic sclerosis"],"prefix":"10.1016","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1049-4676","authenticated-orcid":false,"given":"Giulia","family":"Gasparini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Cozzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"Parodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cyto.2019.154799_b0005","doi-asserted-by":"crossref","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","article-title":"Systemic sclerosis","volume":"1","author":"Allanore","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.cyto.2019.154799_b0010","series-title":"Dermatology","author":"Bolognia","year":"2017"},{"key":"10.1016\/j.cyto.2019.154799_b0015","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJMoa1114576","article-title":"Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis","volume":"370","author":"van Bon","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cyto.2019.154799_b0020","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1007\/s12026-017-8926-y","article-title":"Pathogenesis of systemic sclerosis-current concept and emerging treatments","volume":"65","author":"Furue","year":"2017","journal-title":"Immunol. Res."},{"key":"10.1016\/j.cyto.2019.154799_b0025","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/biof.1117","article-title":"Role of interleukin-13 in fibrosis, particularly systemic sclerosis","volume":"39","author":"O\u2019Reilly","year":"2013","journal-title":"Biofactors"},{"key":"10.1016\/j.cyto.2019.154799_b0030","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1001\/archderm.1996.03890310088013","article-title":"Expression of interleukin-4 in scleroderma skin specimens and scleroderma fibroblast cultures. potential role in fibrosis","volume":"132","author":"Salmon-Ehr","year":"1996","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.cyto.2019.154799_b0035","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1093\/hmg\/ddp119","article-title":"The STAT4 gene influences the genetic predisposition to systemic sclerosis phenotype","volume":"18","author":"Rueda","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.cyto.2019.154799_b0040","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00011-015-0806-0","article-title":"Role of anti-inflammatory cytokines IL-4 and IL-13 in systemic sclerosis","volume":"64","author":"Huang","year":"2015","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.cyto.2019.154799_b0045","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1002\/(SICI)1521-4141(199809)28:09<2619::AID-IMMU2619>3.0.CO;2-M","article-title":"Anti-IL-4 treatment prevents dermal collagen deposition in the tight- skin mouse model of scleroderma","volume":"28","author":"Ong","year":"1998","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.cyto.2019.154799_b0050","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1046\/j.1523-1747.2001.00217.x","article-title":"Lack of skin fibrosis in tight skin (TSK) mice with targeted mutation in the interleukin-4R alpha and transforming growth factor-beta genes","volume":"116","author":"McGaha","year":"2001","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.cyto.2019.154799_b0055","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1002\/art.22927","article-title":"Presence of CD4+CD8+double-positive T cells with very high interleukin-4 production potential in lesional skin of patients with systemic sclerosis","volume":"56","author":"Parel","year":"2007","journal-title":"Arth. Rheum."},{"key":"10.1016\/j.cyto.2019.154799_b0060","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/art.37706","article-title":"Interleukin-13-producing CD81 T cells mediate dermal fibrosis in patients with systemic sclerosis","volume":"65","author":"Fuschiotti","year":"2013","journal-title":"Arth. Rheum."},{"key":"10.1016\/j.cyto.2019.154799_b0065","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/art.37738","article-title":"Tumor necrosis factor\u2013costimulated T lymphocytes from patients with systemic sclerosis trigger collagen production in fibroblasts","volume":"65","author":"Hugle","year":"2013","journal-title":"Arth. Rheum."},{"key":"10.1016\/j.cyto.2019.154799_b0070","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cyto.2019.154799_b0075","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.clim.2011.08.010","article-title":"Treatment with imatinib results in reduced IL-4 producing, but increased CD4+ T cells in the broncho-alveolar lavage of patients with systemic sclerosis","volume":"141","author":"Divekar","year":"2011","journal-title":"Clin. Immunol."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466619302285?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466619302285?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T20:53:43Z","timestamp":1760907223000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466619302285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":15,"alternative-id":["S1043466619302285"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2019.154799","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interleukin-4 and interleukin-13 as possible therapeutic targets in systemic sclerosis","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2019.154799","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"154799"}}